发明申请
- 专利标题： HETEROCYCLIC JANUS KINASE 3 INHIBITORS
- 专利标题（中）： 杂交种JANUS KINASE 3抑制剂
-
申请号： US12065234申请日： 2006-12-25
-
公开(公告)号： US20090270376A1公开(公告)日： 2009-10-29
- 发明人: Takayuki Inoue , Akira Tanaka , Kazuo Nakai , Hiroshi Sasaki , Fumie Takahashi , Shohei Shirakami , Keiko Hatanaka , Yutaka Nakajima , Koichiro Mukoyoshi , Hisao Hamaguchi , Shigeki Kunikawa , Yasuyuki Higashi
- 申请人： Takayuki Inoue , Akira Tanaka , Kazuo Nakai , Hiroshi Sasaki , Fumie Takahashi , Shohei Shirakami , Keiko Hatanaka , Yutaka Nakajima , Koichiro Mukoyoshi , Hisao Hamaguchi , Shigeki Kunikawa , Yasuyuki Higashi
- 申请人地址： JP Chuo-ku
- 专利权人： Astellas Pharma Inc.
- 当前专利权人： Astellas Pharma Inc.
- 当前专利权人地址： JP Chuo-ku
- 优先权： JP2005-378858 20051228
- 国际申请： PCT/JP2006/326327 WO 20061225
- 主分类号： A61K31/437
- IPC分类号： A61K31/437 ; C07D471/04 ; C07D471/14 ; A61K31/496 ; A61K31/5377 ; A61K31/541 ; A61P37/00 ; A61P25/28 ; A61P35/00
摘要：
The present invention provides a compound of formula (I) having an excellent JAK3 inhibition activity and being useful as an active ingredient of an agent for treating and/or preventing various immune diseases including autoimmune diseases inflammatory diseases, and allergic diseases. The compound according to the present invention has an inhibition activity against JAK3 and is thus useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transmission (e.g., rejection during organ/tissue transplantation, autoimmune diseases, multiple sclerosis, rheumatoid arthritis, psoriasis, asthma, atopic dermatitis, Alzheimer's disease, and atherosclerotic disease), or diseases caused by abnormal cytokine signal transmission (e.g., cancer and leukemia).
公开/授权文献
- US07879844B2 Heterocyclic janus kinase 3 inhibitors 公开/授权日：2011-02-01
信息查询
IPC分类:
